AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12003701 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 0
Study 9865456 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg intravenous dose of methylprednisolone (Phase II)
Number of subjects: 12
Study 7711991 — intervention group
Group type: EXPERIMENTAL
Intervention: sustained-release diltiazem 180 mg
Number of subjects: 20
Study 7711991 — intervention group
Group type: COMPARATOR
Intervention: sustained-release nicardipine 40 mg
Number of subjects: 20
Study 2403775 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate (30 mg, intramuscularly)
Number of subjects: 12
Study 2403775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 354483 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid, 6 gm daily for 14 to 21 days
Number of subjects: 39
Study 354483 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (bedrest, dexamethasone when cerebral edema developed, plus isotonic saline)
Number of subjects: 39
Study 31360707 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: Three parallel partial thread screws (PTSs) with intact posteromedial cortex
Number of subjects: 24
Study 31360707 — intervention group
Group type: COMPARATOR
Intervention: Group B: Same fixation of cannulated screws (CSs) as group A but with removed posteromedial cortex
Number of subjects: 24
Study 31360707 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: Two inferior PTSs replaced by two fully thread screws (FTSs)
Number of subjects: 24
Study 28533108 — intervention group
Group type: EXPERIMENTAL
Intervention: xylazine (1 mg kg−1) and tiletamine–zolazepam (8 mg kg−1) with hyaluronidase (400 IU)
Number of subjects: 6
Study 28533108 — intervention group
Group type: COMPARATOR
Intervention: xylazine (1 mg kg−1) and tiletamine–zolazepam (8 mg kg−1) (control treatment, CON)
Number of subjects: 6
Study 26385029 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg twice daily
Number of subjects: 416
Study 26385029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study 25110952 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate beverage (CHOb)
Number of subjects: 10
Study 25110952 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage (PLAb)
Number of subjects: 10
Study 25110952 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate capsules (CHOc)
Number of subjects: 10
Study 25110952 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules (PLAc)
Number of subjects: 10
Study 21606323 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime Time intervention (case management services and peer leadership groups)
Number of subjects: 0
Study 19320804 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine supplementation during the first 28 days of life
Number of subjects: 132
Study 19320804 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 132
Study 17300625 — intervention group
Group type: COMPARATOR
Intervention: 0 ml of soya milk (0 g of fat)
Number of subjects: 12
Study 17300625 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of soya milk (0.32 g of fat)
Number of subjects: 12
Study 17300625 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 ml of soya milk (1.28 g of fat)
Number of subjects: 12
Study 17300625 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 ml of soya milk (4.8 g of fat)
Number of subjects: 12
Study 17300625 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml of soya milk (16 g of fat)
Number of subjects: 12
Study 15362961 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 25
Study 15362961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 11165424 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment regimens
Number of subjects: 902
Study 11165424 — intervention group
Group type: EXPERIMENTAL
Intervention: Closeout visit
Number of subjects: 902
Study 9848038 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombospondin-1 (TSP-1)
Number of subjects: 0
Study 9848038 — intervention group
Group type: EXPERIMENTAL
Intervention: CSVTCG receptor
Number of subjects: 0
Study 7862786 — intervention group
Group type: EXPERIMENTAL
Intervention: Level-of-care instrument
Number of subjects: 300
Study 2480239 — intervention group
Group type: EXPERIMENTAL
Intervention: iloprost 6 ng kg‐1 min‐1
Number of subjects: 42
Study 2480239 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study 7351498 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophil chemotactic factor (ECF)
Number of subjects: 0
Study 7351498 — intervention group
Group type: COMPARATOR
Intervention: Activated serum
Number of subjects: 0
Study 31010873 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition program with a transition coordinator
Number of subjects: 205
Study 31010873 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 205
Study 28100507 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-supplement bars (14 mg Fe/day) for 90 days
Number of subjects: 361
Study 28100507 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 361
Study 25538166 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir
Number of subjects: 86
Study 25538166 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir
Number of subjects: 86
Study 25538166 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 86
Study 23011357 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) at a dose of 7.5 mg/week over 12-18 months
Number of subjects: 30
Study 23011357 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 30
Study 21167689 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive enhancement therapy (CET)
Number of subjects: 0
Study 21167689 — intervention group
Group type: COMPARATOR
Intervention: Enriched supportive therapy (EST)
Number of subjects: 0
Study 20214120 — intervention group
Group type: EXPERIMENTAL
Intervention: Olyset long-lasting insecticide-treated bednets
Number of subjects: 8620
Study 20214120 — intervention group
Group type: COMPARATOR
Intervention: Control areas (no bednets)
Number of subjects: 8620
Study 18577202 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-action analysis (TAA) of the surgical technique
Number of subjects: 20
Study 18577202 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal Oriented Phases (GOP) of the surgical procedure
Number of subjects: 20
Study 15131077 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI of MI oocytes
Number of subjects: 0
Study 15131077 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI of rescued IVM MII oocytes
Number of subjects: 0
Study 15131077 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI of mature MII oocytes
Number of subjects: 0
Study 15131077 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrested IVM MI oocytes
Number of subjects: 0
Study 11448476 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate (Tigason) treatment
Number of subjects: 0
Study 11448476 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate (Tigason) in vitro
Number of subjects: 0
Study 11448476 — intervention group
Group type: COMPARATOR
Intervention: Topically treated psoriatics (control group)
Number of subjects: 0
Study 11448476 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 0
Study 9574374 — intervention group
Group type: COMPARATOR
Intervention: Early elective surgery
Number of subjects: 155
Study 9574374 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 155
Study 8368641 — intervention group
Group type: EXPERIMENTAL
Intervention: LTD4 inhalation
Number of subjects: 0
Study 8368641 — intervention group
Group type: EXPERIMENTAL
Intervention: PAF inhalation
Number of subjects: 0
Study 11693896 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg) via 15‐minute intravenous infusion
Number of subjects: 1648
Study 11693896 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate (90 mg) via 2‐hour intravenous infusion
Number of subjects: 1648
Study 11693896 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg) and pamidronate
Number of subjects: 1648
Study 11693896 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg)
Number of subjects: 1648
Study 11693896 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 1648
Study 30802201 — intervention group
Group type: COMPARATOR
Intervention: Test formulation (new tablet)
Number of subjects: 40
Study 30802201 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (original capsule)
Number of subjects: 40
Study 30802201 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations under fed condition
Number of subjects: 40
Study 28351544 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 38
Study 28351544 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 38
Study 24589044 — intervention group
Group type: EXPERIMENTAL
Intervention: Octenidine wound gel plus modern wound-phase-adapted dressings (treatment arm 2)
Number of subjects: 49
Study 24589044 — intervention group
Group type: EXPERIMENTAL
Intervention: Octenidine wound gel alone (treatment arm 3)
Number of subjects: 49
Study 24589044 — intervention group
Group type: COMPARATOR
Intervention: Modern wound-phase-adapted dressings alone (treatment arm 1)
Number of subjects: 49
Study 24589044 — intervention group
Group type: EXPERIMENTAL
Intervention: Octenidine wound gel treatment (treatment arms 2 and 3)
Number of subjects: 49
Study 24184063 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent electrical stimulation (CES)
Number of subjects: 15
Study 24184063 — intervention group
Group type: COMPARATOR
Intervention: Inactive device (control group)
Number of subjects: 15
Study 22820596 — intervention group
Group type: EXPERIMENTAL
Intervention: Painless urethral catheter placement combined with bladder washing with lidocaine
Number of subjects: 120
Study 22820596 — intervention group
Group type: COMPARATOR
Intervention: Routine catheter placement only
Number of subjects: 120
Study 20798027 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace intervention (n=73)
Number of subjects: 145
Study 20798027 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=72)
Number of subjects: 145
Study 17367349 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 51
Study 17367349 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-filtered P-wave duration (FPD) >150 ms
Number of subjects: 51
Study 17367349 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D electroanatomic mapping (3D-EAM)
Number of subjects: 51
Study 16080809 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ combination tablets (COAPROVEL)
Number of subjects: 920
Study 12413243 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment 1 (riluzole, dosage not specified)
Number of subjects: 0
Study 12413243 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment 2 (riluzole, dosage not specified)
Number of subjects: 0
Study 12413243 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 10543927 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months supervised outpatient group training programme, 50 min three times a week (n=29)
Number of subjects: 65
Study 10543927 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=36)
Number of subjects: 65
Study 8552456 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodal completion
Number of subjects: 0
Study 8552456 — intervention group
Group type: COMPARATOR
Intervention: Non-forced-choice paradigm without feedback
Number of subjects: 0
Study 2333674 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioversol
Number of subjects: 80
Study 2333674 — intervention group
Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 80
Study 380872 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% hydrocortisone cream
Number of subjects: 54
Study 380872 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% clobetasone butyrate (Eumovate)
Number of subjects: 54
Study 31488427 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 167
Study 31488427 — intervention group
Group type: COMPARATOR
Intervention: Topical medication
Number of subjects: 167
Study 31852499 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass drug administration for malaria transmission interruption
Number of subjects: 0
Study 27762570 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat of accusation of misconduct (Experiment 1)
Number of subjects: 476
Study 27762570 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulatory decline during questioning (Experiment 2)
Number of subjects: 476
Study 25858494 — intervention group
Group type: EXPERIMENTAL
Intervention: Inorganic nitrate (NO3 (‐)) supplementation via beetroot juice (8.4 mmol NO3 (‐)/day)
Number of subjects: 7
Study 25858494 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 7
Study 23357841 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg sirukumab
Number of subjects: 49
Study 23357841 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sirukumab
Number of subjects: 49
Study 23357841 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sirukumab
Number of subjects: 49
Study 23357841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 21258039 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsion combining glycerol and paraffin applied twice daily for 7 days
Number of subjects: 100
Study 21258039 — intervention group
Group type: COMPARATOR
Intervention: Emulsion alone (comparator) applied twice daily for 7 days
Number of subjects: 100
Study 21258039 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsion combining glycerol and paraffin
Number of subjects: 100
Study 19549643 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia PCA with opioids (fentanyl 6 microg ml(‐1) and tramadol 3 mg ml(‐1))
Number of subjects: 48
Study 19549643 — intervention group
Group type: COMPARATOR
Intervention: Combined general/epidural anaesthesia plus patient‐controlled epidural analgesia (PCEA)
Number of subjects: 48
Study 19549643 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia PCA with opioids (fentanyl and tramadol)
Number of subjects: 48
Study 17578937 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic pulsed current (PC) with a frequency of 50 Hz and a phase duration of 500 microseconds
Number of subjects: 19
Study 17578937 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst-modulated alternating current (BMAC) (1-kHz alternating current, burst modulated at a frequency of 50 Hz with a 20% duty cycle)
Number of subjects: 19
Study 17578937 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PC and BMAC
Number of subjects: 19
Study 15631774 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotropin (6 ml, IV, QD for 2 weeks, then 2 tablets, BID for another 2 weeks)
Number of subjects: 95
Study 15631774 — intervention group
Group type: COMPARATOR
Intervention: Methycobal (1 ml, IM, QD for 2 weeks, then 1 tablet TID for another 2 weeks)
Number of subjects: 95
Study 15631774 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotropin
Number of subjects: 95
Study 15631774 — intervention group
Group type: COMPARATOR
Intervention: Methycobal
Number of subjects: 95
Study 11494088 — intervention group
Group type: EXPERIMENTAL
Intervention: Right arm blood pressure measurement
Number of subjects: 237
Study 11494088 — intervention group
Group type: COMPARATOR
Intervention: Left arm blood pressure measurement
Number of subjects: 237
Study 11494088 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-arm difference of 10 mm Hg or greater for diastolic blood pressure
Number of subjects: 237
Study 11494088 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-arm difference of 20 mm Hg or more for systolic blood pressure
Number of subjects: 237
Study 9210750 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 ml/kg of alcohol
Number of subjects: 40
Study 9210750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8135469 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg Aminoglutethimide (AG) daily
Number of subjects: 106
Study 8135469 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg Aminoglutethimide (AG) daily
Number of subjects: 106
Study 8135469 — intervention group
Group type: COMPARATOR
Intervention: Cortisone Acetate (CA) replacement dose 37.5 mg/day orally (used in both groups)
Number of subjects: 106
Study 3479419 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin 750 mg bid
Number of subjects: 18
Study 3479419 — intervention group
Group type: COMPARATOR
Intervention: Oral ofloxacin 400 mg bid
Number of subjects: 18
Study 31077229 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring
Number of subjects: 0
Study 31077229 — intervention group
Group type: EXPERIMENTAL
Intervention: Unattended automated blood pressure monitoring (uAOBP)
Number of subjects: 0
Study 31077229 — intervention group
Group type: EXPERIMENTAL
Intervention: Central BP-guided treatment
Number of subjects: 0
Study 29231429 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Acupuncture
Number of subjects: 50
Study 29231429 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 50
Study 25458463 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled glutathione (GSH)
Number of subjects: 105
Study 25458463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 23785463 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptococcus salivarius M18 (various doses)
Number of subjects: 75
Study 23785463 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptococcus salivarius M18
Number of subjects: 75
Study 23785463 — intervention group
Group type: EXPERIMENTAL
Intervention: Megaplasmid transfer to S. salivarius
Number of subjects: 75
Study 21961534 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EG, n = 52) - supervised aerobic dance and strength training for 60 minutes, twice per week for a minimum of 12 weeks
Number of subjects: 105
Study 21961534 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n = 53)
Number of subjects: 105
Study 19100344 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for 3 months
Number of subjects: 40
Study 19100344 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 40
Study 16502768 — intervention group
Group type: EXPERIMENTAL
Intervention: EZE/SIMVA 10/10 mg/mg
Number of subjects: 96
Study 16502768 — intervention group
Group type: COMPARATOR
Intervention: EZE 10 mg + SIMVA 10 mg
Number of subjects: 96
Study 16502768 — intervention group
Group type: EXPERIMENTAL
Intervention: EZE/SIMVA 10/80 mg/mg
Number of subjects: 96
Study 16502768 — intervention group
Group type: COMPARATOR
Intervention: EZE 10 mg + SIMVA 80 mg
Number of subjects: 96
Study 15337642 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy for suicidal behavior
Number of subjects: 0
Study 15337642 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative study designs (add-on trials)
Number of subjects: 0
Study 10551700 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and angiographic follow-up (AF)
Number of subjects: 706
Study 10551700 — intervention group
Group type: COMPARATOR
Intervention: Clinical follow-up (CF)
Number of subjects: 706
Study 8682733 — intervention group
Group type: EXPERIMENTAL
Intervention: DRO schedule with high-preference stimuli associated with high rates of SIB (HP/HS)
Number of subjects: 2
Study 8682733 — intervention group
Group type: EXPERIMENTAL
Intervention: DRO schedule with low-preference stimuli associated with low rates of SIB (LP/LS)
Number of subjects: 2
Study 1998637 — intervention group
Group type: EXPERIMENTAL
Intervention: External cephalic version (ECV) attempted after intravenous injection of 10 micrograms of hexaprenaline.
Number of subjects: 208
Study 1998637 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention mentioned).
Number of subjects: 208
Study 6677076 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram (250 mg)
Number of subjects: 14
Study 6677076 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual ratings
Number of subjects: 14
Study 31016337 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization exercise (SE)
Number of subjects: 68
Study 31016337 — intervention group
Group type: COMPARATOR
Intervention: General exercise (GE)
Number of subjects: 68
Study 31482956 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin (Hb) levels
Number of subjects: 49296
Study 31482956 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin (Hb) levels in women
Number of subjects: 49296
Study 31482956 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin (Hb) levels in men
Number of subjects: 49296
Study 28121991 — intervention group
Group type: EXPERIMENTAL
Intervention: Anode Right/Cathode Left (AR/CL) tDCS
Number of subjects: 39
Study 28121991 — intervention group
Group type: EXPERIMENTAL
Intervention: Anode Left/Cathode Right (AL/CR) tDCS
Number of subjects: 39
Study 28121991 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 39
Study 28121991 — intervention group
Group type: EXPERIMENTAL
Intervention: AR/CL tDCS
Number of subjects: 39
Study 28121991 — intervention group
Group type: EXPERIMENTAL
Intervention: AL/CR tDCS
Number of subjects: 39
Study 28121991 — intervention group
Group type: EXPERIMENTAL
Intervention: All tDCS sessions
Number of subjects: 39
Study 25886901 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 mg/kg
Number of subjects: 500
Study 25886901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 23080334 — intervention group
Group type: EXPERIMENTAL
Intervention: Basilic vein transposition (BVT)
Number of subjects: 60
Study 23080334 — intervention group
Group type: COMPARATOR
Intervention: Arteriovenous access grafts (AVG)
Number of subjects: 60
Study 21121925 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-training program (PT)
Number of subjects: 186
Study 21121925 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 186